Acrivon reports $169.6M cash, runway into Q4 2024; ACR-368 OncoSignature enriches ORR to 47-58% in ovarian cancer

Acrivon Therapeutics, Inc.

Cash and marketable securities $169.6M as of Dec 31, 2022 (preliminary, unaudited); projected runway into at least Q4 2024.
ACR-368 OncoSignature test enriched ORR to 47% (NCI) and 58% (Lilly) in blinded studies of platinum-resistant ovarian cancer biopsies.
Registrational-intent Phase 2 single-arm trials of ACR-368 monotherapy in OncoSignature-positive patients planned for ovarian, endometrial, bladder, and HPV SCC cancers.
Internal WEE1 and PKMYT1 inhibitors advancing to IND-enabling studies in 2023.
Past Phase 2 all-comer ORR for ACR-368 in platinum-resistant ovarian cancer was 12.1%; mDoR 5.6 months.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.